Epileptic Syndromes: Clinical Trials

76 trials for Epileptic Syndromes, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

33 completed, 18 terminated, 7 unknown, 6 withdrawn. 76 Phase 3, 11 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 376Completed 33, Terminated 18, Unknown 7, Withdrawn 6, Active not recruiting 5, Recruiting 5, Enrolling by invitation 1, Suspended 1
Phase 211Unknown 5, Terminated 3, Completed 1, Recruiting 1, Withdrawn 1

Follow Epileptic Syndromes: new trials by email Literature Review of Epileptic Syndromes trials Research Report on Epileptic Syndromes

Trials (filtered) newest first · largest first

All 76 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy
JZP926 capsule, Placebo - Juvenile Myoclonic Epilepsy
Phase 2 / Phase 3RecruitingJazz Pharmaceuticals2602026-09-182026-11-12
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
zorevunersen, Sham Comparator - Dravet Syndrome
Phase 3Active not recruitingStoke Therapeutics, Inc1702025-06-042026-10-20
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
Clemizole HCl, Placebo - Lennox Gastaut Syndrome
Phase 3RecruitingEpygenix2602025-04-092026-10-09
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
LP352 - Developmental and Epileptic Encephalopathy
Phase 3Enrolling by invitationLongboard Pharmaceuticals3242025-02-122026-10-14
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
LP352, Placebo - Developmental and Epileptic Encephalopathy
Phase 3Active not recruitingLongboard Pharmaceuticals3672024-11-112026-09-15
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
LP352, Placebo - Dravet Syndrome
Phase 3Active not recruitingLongboard Pharmaceuticals1082024-09-252026-10-27
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Brivaracetam Film-coated tablet, Brivaracetam oral solution - Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Phase 3Active not recruitingUCB Biopharma SRL702024-07-102026-08-27
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
BHV-7000, Placebo - Generalized Epilepsy
Phase 2 / Phase 3TerminatedBiohaven Therapeutics Ltd.272024-06-202026-03-24
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
fenfluramine - Dravet Syndrome
Phase 3CompletedUCB BIOSCIENCES, Inc.252024-05-212026-09-17
A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine
Soticlestat - Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
Phase 3TerminatedTakeda12024-04-252026-09-04
Cortical Excitability in West Syndrome Using Transcranial Magnetic Stimulation
ACTH/Oral Steroids - West Syndrome
Phase 2 / Phase 3UnknownAll India Institute of Medical Sciences402024-03-012024-03-04
Modified Atkins Diet Versus Topiramate In Children With Epileptic Spasms Refractory To Hormonal Treatment: A Randomized Open-Label Study
Modified Atkins diet, Topiramate - Epileptic Spasms, Failed Hormonal Therapy
Phase 2 / Phase 3UnknownLady Hardinge Medical College702023-07-202023-07-24
A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms
AMZ002 injectable solution, 0.5mg/mL, Vigabatrin, oral - Spasms, Infantile
Phase 3WithdrawnAmzell2023-04-012023-04-20
Fenfluramine for Adult Dravet Patients
Fenfluramine - Dravet Syndrome, Dravet Syndrome, Intractable
Phase 3TerminatedUniversity Health Network, Toronto72023-01-112026-05-05
Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
GWP42003-P, Placebo - Seizures Associated With EMAS
Phase 3TerminatedJazz Pharmaceuticals32022-10-312025-02-03
A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
Vatiquinone - Inherited Mitochondrial Disease
Phase 3CompletedPTC Therapeutics1012022-06-222025-12-22
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Carisbamate - Seizures, Lennox Gastaut Syndrome
Phase 3RecruitingSK Life Science, Inc.2522022-04-282026-11-06
Ketogenic Diet vs ACTH for the Treatment of Children With West Syndrome
Ketogenic diet, ACTH - Ketogenic Diet, West Syndrome
Phase 2 / Phase 3UnknownAll India Institute of Medical Sciences802022-04-182024-06-25
A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Brivaracetam Film-coated tablet, Brivaracetam oral solution - Childhood Absence Epilepsy, Juvenile Absence Epilepsy
Phase 3CompletedUCB Biopharma SRL842022-03-302025-10-22
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
Fenfluramine, Placebo - CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure
Phase 3Active not recruitingZogenix, Inc.872022-03-082026-04-29

Showing 20 of 76. Sign in to see all of them.

Narrower conditions

Epilepsy (30)  ·  Seizures (28)  ·  Epilepsies, Myoclonic (25)  ·  Lennox Gastaut Syndrome (25)  ·  Spasms, Infantile (17)  ·  Brain Diseases (6)  ·  Epilepsy, Absence (6)  ·  Central Nervous System Diseases (3)  ·  Drug Resistant Epilepsy (3)  ·  Myoclonic Epilepsies, Progressive (3)  ·  Neurodevelopmental Disorders (3)  ·  Unverricht-Lundborg Syndrome (3)  ·  Diffuse Cerebral Sclerosis of Schilder (2)  ·  Disease (2)

Broader conditions

Nervous System Diseases (74)  ·  Central Nervous System Diseases (73)  ·  Brain Diseases (70)  ·  Epilepsy, Generalized (52)  ·  Epilepsy (46)  ·  Pathological Conditions, Signs and Symptoms (32)  ·  Signs and Symptoms (32)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (31)  ·  Neurologic Manifestations (31)  ·  Genetic Diseases, Inborn (30)  ·  Epilepsies, Myoclonic (7)  ·  Heredodegenerative Disorders, Nervous System (4)  ·  Neurodegenerative Diseases (4)  ·  Pathologic Processes (4)

Interventions

Cannabidiol (14)  ·  Fenfluramine (8)  ·  brivaracetam (5)  ·  Clobazam (4)  ·  Vigabatrin (4)  ·  soticlestat (4)  ·  Prednisolone (3)  ·  Topiramate (3)  ·  ezogabine (3)  ·  rufinamide (3)  ·  Diet, Ketogenic (2)  ·  Ethosuximide (2)  ·  Lamotrigine (2)  ·  Valproic Acid (2)  ·  alpha-tocotrienol quinone (2)

Sponsors

Jazz Pharmaceuticals (9)  ·  Lady Hardinge Medical College (5)  ·  Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. (5)  ·  Takeda (4)  ·  All India Institute of Medical Sciences (3)  ·  Eisai Inc. (3)  ·  INSYS Therapeutics Inc (3)  ·  Longboard Pharmaceuticals (3)  ·  UCB Biopharma SRL (3)  ·  Epygenix (2)  ·  H. Lundbeck A/S (2)  ·  Lundbeck LLC (2)  ·  PTC Therapeutics (2)  ·  Xenon Pharmaceuticals Inc. (2)  ·  Zogenix, Inc. (2)

Countries

United States (51)  ·  Italy (27)  ·  Spain (25)  ·  France (21)  ·  Canada (19)  ·  Poland (18)  ·  Australia (17)  ·  Germany (17)  ·  Japan (16)  ·  United Kingdom (16)  ·  Belgium (15)  ·  India (14)  ·  Netherlands (14)  ·  Mexico (10)  ·  China (9)

Top investigators

Neha Parikh (3)  ·  Amit Ray, MD (2)  ·  Hiroki Takano (2)  ·  Satinder Aneja, MD (2)  ·  Suvasini Sharma, MD, DM (2)  ·  Vinay Penematsa, MD (2)  ·  Alexis Arzimanoglou Arzimanoglou (1)  ·  Avital Cnaan, PhD (1)  ·  Carter Snead, MD (1)  ·  Dipti Kapoor, MD (1)

Results publications

PMID 33825230, PMID 34768178, PMID 26666500, PMID 27683846, PMID 29768152, PMID 33461041, PMID 33540241, PMID 33797076, PMID 34265088, PMID 37052803, PMID 40775196, PMID 10371538, PMID 20200383, PMID 21920781, PMID 21956725, PMID 22396514, PMID 23141144, PMID 25048310, PMID 26805435, PMID 28538134, PMID 28916534, PMID 29547159, PMID 30309816, PMID 30955420, PMID 31168494, PMID 31790543, PMID 31862249, PMID 32119035, PMID 33179247, PMID 33575989, PMID 33834913, PMID 34287833, PMID 34406656, PMID 34554571, PMID 34676542, PMID 35499850, PMID 35844134, PMID 37543865, PMID 40072476, PMID 40840039

NIH funding

2014 (6), 2023 (5), 2015 (2), 2017 (2), 2005 (1), 2016 (1), 2019 (1), U01NS045803 (1)